Breaking News Instant updates and real-time market news.

MRK

Merck

$59.68

(0.00%)

04:55
05/15/18
05/15
04:55
05/15/18
04:55

Merck management to meet with JPMorgan

Meeting to be held in New York on May 15 hosted by JPMorgan.

  • 15

    May

  • 15

    May

  • 05

    Jun

  • 23

    Oct

MRK Merck
$59.68

(0.00%)

04/23/18
GSCO
04/23/18
UPGRADE
Target $73
GSCO
Conviction Buy
Goldman upgrades Merck to Buy, puts on Conviction List with $73 target
Goldman Sachs analyst Jami Rubin upgraded Merck to Buy from Neutral and added the shares to her firm's Conviction List. Rubin also upped her price target for the shares to $73 from $63. Merck closed Friday up 20c to $58.83. The analyst increased her estimates for Keytruda sales by $2B in 2021 and $4B in 2025. The narrative for Merck is "quickly changing with the success of Keytruda, driving a significant shift in product mix from a large primary care evolving into a specialty biopharma," Rubin tells investors in a research note. The analyst now sees "significant" margin upside from product mix shift with higher Keytruda sales than previously modeled. She believes Merck's operating margins could go from 32.5% in 2017 to 40% by 2025, with an inflection point beginning in the second half of 2018.
04/25/18
DBAB
04/25/18
NO CHANGE
DBAB
Hold
Merck may need to reassess animal health unit, says Deutsche Bank
While Merck (MRK) describes its animal health unit as a key growth driver and an important part of the company, it remains to be seen whether investors will continue to accept this as a reason for the business to remain within the company, Deutsche Bank analyst Gregg Gilbert tells investors in a research note. He believes the unit is potentially undervalued. Given Zoetis' (ZTS) success as a company and a stock, and Eli Lilly's (LLY) ongoing review of strategic options for its Elanco Animal Health business, Gilbert conducted a preliminary separation analysis of Merck's animal health unit. The analysis suggests that a separation could be meaningfully accretive to earnings. The analyst keeps a Hold rating on Merck.
04/26/18
BMOC
04/26/18
NO CHANGE
Target $70
BMOC
Outperform
Merck price target raised to $70 from $65 at BMO Capital
BMO Capital analyst Alex Arfaei raised his price target on Merck to $70 and kept his Outperform rating, forecasting a "mixed to net-positive" Q1 earnings report. The analyst notes the focus will likely fall on the core Keytruda and Januvia franchises as he raises his peak sales estimate for the former to $13B from $12B after KN-189 data, which he expects to be further supported by discussions at ASCO.
05/10/18
STFL
05/10/18
NO CHANGE
STFL
Hold
Exelixis pullback may create interesting entry point, says Stifel
After Exelixis (EXEL) and partner Roche (RHHBY) announced the Phase 3 IMblaze370 trial did not achieve statistical-significance on the primary efficacy endpoint evaluating the ability of a combination of a MEK inhibitor and anti-PD-L1 to improve overall survival in patients with microsatellite stable metastatic colorectal cancer, Stifel analyst Stephen Willey said he believes attrition in Exelixis shares might create an interesting entry point. The failure of IMblaze370 removes some of Exelixis' longer-term optionality and he expects topics of RCC growth/competition, label expansion, and longer-term cabozantinib exclusivity to remain core to the story going forward, said Willey who has a Hold rating on the stock. Array BioPharma (ARRY) also has Phase 1/2 development collaborations in place with both Bristol-Myers (BMY) and Merck (MRK) evaluating the MEK/PD-1 hypothesis in earlier-lines of MSS mCRC, noted Willey, who said he would "be opportunistic" on any weakness in its shares. He maintains a Buy rating on Array, which is down 5% in pre-market trading.

TODAY'S FREE FLY STORIES

EGL

Engility

$30.17

0.33 (1.11%)

07:01
05/25/18
05/25
07:01
05/25/18
07:01
Initiation
Engility initiated  »

Engility initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NUGT

Direxion Gold Miners Bull

$26.22

1.04 (4.13%)

07:01
05/25/18
05/25
07:01
05/25/18
07:01
Technical Analysis
Direxion Gold Miners Bull: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JNUG

Direxion Daily Jr Gld Mnrs Bull 3X Shrs

$14.87

0.54 (3.77%)

07:00
05/25/18
05/25
07:00
05/25/18
07:00
Technical Analysis
Direxion Daily Jr Gld Mnrs Bull 3X Shrs: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DUST

Direxion Daily Gold Miners Bear 3X ETF

$23.22

-0.99 (-4.09%)

07:00
05/25/18
05/25
07:00
05/25/18
07:00
Technical Analysis
Direxion Daily Gold Miners Bear 3X ETF: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JDST

Direxion Daily Junior Gold Miners Index Bear 3x Shares

$47.36

-1.79 (-3.64%)

06:59
05/25/18
05/25
06:59
05/25/18
06:59
Technical Analysis
Direxion Daily Junior Gold Miners Index Bear 3x Shares: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FB

Facebook

$185.96

-0.94 (-0.50%)

06:59
05/25/18
05/25
06:59
05/25/18
06:59
Periodicals
Zuckerberg says 'vast majority' of users opt into invasive features, BI reports »

Facebook CEO Mark…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Jun

VXX

iPath S&P 500 VIX Short-Term Futures

$33.82

-0.18 (-0.53%)

06:59
05/25/18
05/25
06:59
05/25/18
06:59
Technical Analysis
iPath S&P 500 VIX Short-Term Futures: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CNI

Canadian National

$83.75

-0.4 (-0.48%)

06:58
05/25/18
05/25
06:58
05/25/18
06:58
Upgrade
Canadian National rating change  »

Deutsche upgrades…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    May

ARLP

Alliance Resource Partners

$18.25

-0.45 (-2.41%)

06:58
05/25/18
05/25
06:58
05/25/18
06:58
Conference/Events
Alliance Resource Partners management to meet with Seaport Global »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    May

SPLK

Splunk

$116.35

-0.2 (-0.17%)

06:58
05/25/18
05/25
06:58
05/25/18
06:58
Recommendations
Splunk analyst commentary  »

Splunk price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Jul

TVIX

VelocityShares Daily 2x VIX Short-Term ETN

$4.74

-0.02 (-0.42%)

06:58
05/25/18
05/25
06:58
05/25/18
06:58
Technical Analysis
VelocityShares Daily 2x VIX Short-Term ETN: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SVXY

ProShares Short VIX Short-Term Futures

$13.59

0.03 (0.22%)

06:58
05/25/18
05/25
06:58
05/25/18
06:58
Technical Analysis
ProShares Short VIX Short-Term Futures: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

USO

United States Oil Fund

$14.29

-0.225 (-1.55%)

06:57
05/25/18
05/25
06:57
05/25/18
06:57
Technical Analysis
United States Oil Fund: Pivot points, pivot low broken »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AZN

AstraZeneca

$36.88

0.035 (0.09%)

06:57
05/25/18
05/25
06:57
05/25/18
06:57
Hot Stocks
AstraZeneca says Imfinzi met second primary endpoint in PACIFIC trial »

AstraZeneca and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Jun

XOP

SPDR Oil Exploration and Production Fund

$42.27

-0.53 (-1.24%)

06:56
05/25/18
05/25
06:56
05/25/18
06:56
Technical Analysis
SPDR Oil Exploration and Production Fund: Pivot points, pivot low broken »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DGAZ

VelocityShares 3x Inv Natural Gas ETN

$22.23

-0.25 (-1.11%)

06:56
05/25/18
05/25
06:56
05/25/18
06:56
Technical Analysis
VelocityShares 3x Inv Natural Gas ETN: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BKE

The Buckle

$25.75

0.65 (2.59%)

06:56
05/25/18
05/25
06:56
05/25/18
06:56
Earnings
The Buckle reports Q1 EPS 38c, consensus 36c »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    May

UGAZ

VelocityShares 3x Long Natural Gas ETN

$68.48

0.96 (1.42%)

06:55
05/25/18
05/25
06:55
05/25/18
06:55
Technical Analysis
VelocityShares 3x Long Natural Gas ETN: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FQVLF

First Quantum Minerals

$0.00

(0.00%)

06:55
05/25/18
05/25
06:55
05/25/18
06:55
Downgrade
First Quantum Minerals rating change  »

First Quantum Minerals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

06:55
05/25/18
05/25
06:55
05/25/18
06:55
General news
FX Action: USD-CAD clawed out an 11-day high »

FX Action: USD-CAD clawed…

EWZ

MSCI Brazil Index

$38.16

-0.52 (-1.34%)

06:54
05/25/18
05/25
06:54
05/25/18
06:54
Technical Analysis
MSCI Brazil Index: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EFA

iShares MSCI EAFE Index Fund

$70.66

-0.26 (-0.37%)

06:54
05/25/18
05/25
06:54
05/25/18
06:54
Technical Analysis
iShares MSCI EAFE Index Fund: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FL

Foot Locker

$46.38

1.35 (3.00%)

06:53
05/25/18
05/25
06:53
05/25/18
06:53
Hot Stocks
Foot Locker provides store base update »

During Q1, Foot Locker…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    May

JNK

SPDR Barclays High Yield Bond

$35.75

(0.00%)

06:53
05/25/18
05/25
06:53
05/25/18
06:53
Technical Analysis
SPDR Barclays High Yield Bond: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SJB

ProShares Short High Yield

$23.18

(0.00%)

06:53
05/25/18
05/25
06:53
05/25/18
06:53
Technical Analysis
ProShares Short High Yield: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.